Home>Topics>Companies>AstraZeneca

AstraZeneca

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
  1. 4 Companies Leading the Next Wave of Cancer-Drug Innovation

    Video Reports

    Thu, 21 May 2015

    RHHBY), and [TICKER:AZN] AstraZeneca (AZN) as well. So, those are ..... that Roche and [TICKER:AZN] AstraZeneca are very well positioned. Merck ..... opportunities. [TICKER:AZN] AstraZeneca and Roche are also toward the forefront

    Astrazeneca found at 0:57, 4:19

    is [TICKER:BMY] Bristol-Myers (BMY). Along with Bristol, there's Merck (MRK), [TICKER:RHHBY] Roche (RHHBY), and [TICKER:AZN] AstraZeneca (AZN) as well. So, those are the four names that we see as really leading this next wave of innovation in immuno-oncology.
    positioned for combination therapy are, again, Bristol--very well positioned--after that Roche and [TICKER:AZN] AstraZeneca are very well positioned. Merck is well in the lead with immuno-oncology but doesn't have quite as many combinations as those other three companies have. Coffina: Great. Thanks for joining me, Damien. Conover: Matt, thanks for having me. Coffina: So, in conclusion, we think immuno-oncology is a particularly promising area for growth for pharmaceutical firms and that Bristol-Myers and Merck look like some of the best investment opportunities. [TICKER:AZN] AstraZeneca and Roche are also toward the forefront of developing these drugs. For Morningstar StockInvestor , I'm Matt Coffina. Thanks for joining us.
  2. AstraZeneca to invest $285 million in Swedish biotech drug factory

    Headlines

    Mon, 18 May 2015

    LONDON (Reuters) - AstraZeneca is investing $285 million to expand biotech drug manufacturing in Sweden as the company bets on the future of high-tech medicine for future growth.

  3. UPDATE 1- AstraZeneca to invest $285 mln in Swedish biotech drug factory

    Headlines

    Mon, 18 May 2015

    LONDON, May 18 (Reuters) - AstraZeneca is investing $285 million to expand biotech drug manufacturing in Sweden as the company bets on the future of high-tech medicine for future growth.

  4. CORRECTED-BRIEF- Astrazeneca to invest $285 mln in biologics facility in Sweden

    Headlines

    Mon, 18 May 2015

    * To invest in new biologics manufacturing facility in Södertälje, Sweden, to support accelerating biologics portfolio

  5. AstraZeneca to invest $285 mln in Swedish biotech factory

    Headlines

    Mon, 18 May 2015

    LONDON, May 18 (Reuters) - AstraZeneca is investing $285 million to expand biotech drug manufacturing in Sweden as the company bets on the future of high-tech medicine for future growth.

  6. BRIEF- AstraZeneca to invest in biologics manufacturing facility in Sweden

    Headlines

    Mon, 18 May 2015

    * Astrazeneca to invest in new biologics manufacturing facility in Södertälje, Sweden, to support accelerating biologics portfolio

  7. UPDATE 2-U.S. FDA warns on newer class of type 2 diabetes drugs

    Headlines

    Fri, 15 May 2015

    May 15 (Reuters) - The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drugs sold by AstraZeneca , Johnson & Johnson and Eli Lilly in partnership...

  8. U.S. FDA warns on newer class of type 2 diabetes drugs

    Headlines

    Fri, 15 May 2015

    May 15 (Reuters) - The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drug sold by AstraZeneca , Johnson & Johnson and Eli Lilly in partnership...

  9. Strong ASCO Data Supports Our Above-Consensus IO Sales Projections; Merck Looks Most Undervalued

    Commentary

    Thu, 14 May 2015

    several types of cancer. Further, the data reinforces our wide economic moats for Bristol-Myers, Roche, Merck, and AstraZeneca , as it not only looks strong enough for approval of each of these companies' leading IO drugs, but also should support

  10. AstraZeneca drug combination on track to fight lung cancer

    Headlines

    Wed, 13 May 2015

    May 13 (Reuters) - A closely watched immune system-boosting drug cocktail from Britain's AstraZeneca shows promise in advanced lung cancer, despite adverse side effects in a number of patients.

« Prev12345Next »
Content Partners